PharmaVOICE - January 2014
By Robin Robinson
In November 2013, Wellspring Biosciences discovered small molecules that bind irreversibly to a common oncogenic mutant, K-Ras G12C, one of the most promising approaches to target K-Ras yet reported. The finding was facilitated by Wellspring’s participation in Janssen Labs’ incubator program at its West Coast Research Center, which provides a capital-efficient, resource-rich environment for independent emerging companies to progress their research. Within this innovative environment, Wellspring was able to achieve this discovery in a matter of months...